AZ, Lilly's BACE Inhibitor Clears Safety Hurdle And Raises Class Hopes
This article was originally published in Scrip
AstraZeneca and Eli Lilly are to plough straight ahead with the Phase III part of the AMARANTH study testing their oral beta secretase cleaving enzyme (BACE) inhibitor AZD3293 in early Alzheimer's after an encouraging interim safety review, building confidence in this potential disease-modifying drug class.
You may also be interested in...
Lilly’s new CEO David Ricks said he had confidence in the Trump Administration’s ability to understand and respond to the biopharma industry’s needs as well as address drug pricing concerns. The company’s fourth quarter earnings could insulate it from cost criticism, since sales volume drove revenue gains, not prices.
Undaunted by its recent disappointment with solanezumab, Eli Lilly is adding another clinical-stage Alzheimer's disease candidate to its portfolio through an agreement with AstraZeneca.
Lilly will make its first presentation of solanezumab data from the recently failed Phase III EXPEDITION3 study during the Clinical Trials in Alzheimer’s Disease meeting where researchers will discuss amyloid beta and other hypotheses in Alzheimer’s disease Dec. 8-10 in San Diego.